Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
Top Page
Aardvark Therapeutics, Inc.
(NASDAQ:AARD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.00
▲(1.52% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak fundamentals for a pre-revenue biotech (rapidly widening losses and accelerating cash burn) and very bearish technicals with the stock far below key moving averages. Valuation is difficult to support with a negative P/E, while corporate events are mixed—financing flexibility and trial expansion are positives, but the Phase 3 pause adds meaningful near-term clinical and timing risk.
Positive Factors
Financing Flexibility
A $150M at-the-market equity program materially increases the company’s ability to fund expensive clinical development without immediate bank financing. Over 2–6 months this provides durable optionality to support trials, program refinements, or strategic hires, reducing short-term liquidity pressure if deployed prudently.
Negative Factors
Pre-revenue with Widening Losses
Aardvark remains pre-commercial with materially widening operating losses, creating sustained reliance on external funding. Over the next several months this negative profitability profile increases execution risk and investor dependence on successful trial readouts or capital markets access to continue operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Financing Flexibility
A $150M at-the-market equity program materially increases the company’s ability to fund expensive clinical development without immediate bank financing. Over 2–6 months this provides durable optionality to support trials, program refinements, or strategic hires, reducing short-term liquidity pressure if deployed prudently.
Read all positive factors
Aardvark Therapeutics, Inc. (AARD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$85.96M
Dividend YieldN/A
Average Volume (3M)166.37K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS Growth31.30%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding21,816,042
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.42
Price to Sales (P/S)0.00
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.04K
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$13.26Price Target Upside236.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.45
Revenue Forecast (FY)N/A
Aardvark Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, ...
Aardvark Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
60
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -36.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -62.73M | -22.65M | -6.65M | -9.76M |
| Net Income | -57.59M | -20.59M | -7.21M | -13.56M |
Balance Sheet | ||||
| Total Assets | 117.18M | 77.51M | 10.54M | 16.76M |
| Cash, Cash Equivalents and Short-Term Investments | 110.03M | 73.66M | 9.99M | 16.11M |
| Total Debt | 441.00K | 779.00K | 162.00K | 262.00K |
| Total Liabilities | 10.55M | 132.15M | 45.34M | 44.68M |
| Stockholders Equity | 106.63M | -54.64M | -34.80M | -27.92M |
Cash Flow | ||||
| Free Cash Flow | -54.27M | -18.20M | -5.82M | -10.54M |
| Operating Cash Flow | -54.17M | -18.09M | -5.82M | -10.54M |
| Investing Cash Flow | -49.67M | -12.00M | 0.00 | -1.00M |
| Financing Cash Flow | 89.25M | 81.99M | 0.00 | 225.00K |
Aardvark Therapeutics, Inc. Risk Analysis
Aardvark Therapeutics, Inc. disclosed 89 risk factors in its most recent earnings report. Aardvark Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aardvark Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $212.83M | -4.17 | -22.37% | ― | 3.36% | 5.15% | |
54 Neutral | $1.45B | ― | 31.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $938.77M | -3.77 | -101.33% | ― | ― | -35.62% | |
49 Neutral | $641.59M | ― | -57.29% | ― | ― | -22.82% | |
44 Neutral | $85.96M | -4.47 | -48.06% | ― | ― | 31.30% |
* Healthcare Sector Average
AARD
Aardvark Therapeutics, Inc.
3.94
-3.68
-48.29%
ANNX
Annexon Biosciences
5.85
4.32
282.35%
NBTX
Nanobiotix
30.34
27.01
811.11%
DRTS
Alpha Tau Medical Ltd
7.29
4.71
182.56%
OABI
OmniAb
1.47
-0.46
-23.83%
Aardvark Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Aardvark Therapeutics Establishes $150 Million Equity Program
Positive
Mar 24, 2026
On March 23, 2026, Aardvark Therapeutics, Inc. entered into an equity distribution agreement with Piper Sandler Co., allowing the company, at its discretion, to offer and sell up to $150 million of its common stock from time to time under an effe...
Business Operations and StrategyProduct-Related Announcements
Aardvark Pauses ARD-101 Phase 3 HERO Trial Enrollment
Negative
Feb 27, 2026
On February 27, 2026, Aardvark Therapeutics said it had voluntarily paused enrollment and dosing in its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, along with the related open-label extension study. The move followed re...
Business Operations and StrategyExecutive/Board Changes
Aardvark Launches Ardia Dermatology Unit, Realigns Leadership
Positive
Feb 12, 2026
On February 9, 2026, Aardvark Therapeutics, Inc. reorganized key leadership roles as Chief Operating Officer Bryan Jones, Ph.D., transitioned to become Chief Executive Officer of its new wholly owned dermatology subsidiary, Ardia Therapeutics, Inc...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Aardvark Expands PWS Phase 3 Trial to Younger Children
Positive
Feb 10, 2026
On February 10, 2026, Aardvark Therapeutics announced that a U.S. Institutional Review Board approved an amended protocol for its ongoing Phase 3 HERO pivotal trial of ARD-101 in Prader-Willi syndrome, following submission of the changes to the Fo...
Business Operations and StrategyProduct-Related Announcements
Aardvark Therapeutics updates investor presentation on hunger therapies
Positive
Jan 12, 2026
On January 12, 2026, Aardvark Therapeutics updated and published a new corporate investor presentation outlining its development pipeline and strategic focus on suppressing hunger to treat Prader–Willi syndrome and obesity. The materials hig...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.